<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332212</url>
  </required_header>
  <id_info>
    <org_study_id>1245-0148</org_study_id>
    <secondary_id>2017-000376-28</secondary_id>
    <nct_id>NCT03332212</nct_id>
  </id_info>
  <brief_title>A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin</brief_title>
  <official_title>EMPA-VISION: A Randomised, Double-blind, Placebo-controlled, Mechanistic Cardiac Magnetic Resonance Study to Investigate the Effects of Empagliflozin Treatment on Cardiac Physiology and Metabolism in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to assess the effect of empagliflozin on cardiac physiology
      and metabolism aiming to provide a scientific explanation of the underlying mechanism by
      which empagliflozin improves HF related outcomes in patients with chronic heart failure
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">March 6, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 27, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to week 12 in PCr/ATP ratio in the resting state measured by 31P MRS.</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Cohort A (Empagliflozin + Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heart Failure with Reduced Ejection Fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (Empagliflozin + Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heart Failure with Preserved Ejection Fraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>12 weeks</description>
    <arm_group_label>Cohort A (Empagliflozin + Placebo)</arm_group_label>
    <arm_group_label>Cohort B (Empagliflozin + Placebo)</arm_group_label>
    <other_name>JARDIANCE, JARDIANZ, GIBTULIO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>12 Weeks</description>
    <arm_group_label>Cohort A (Empagliflozin + Placebo)</arm_group_label>
    <arm_group_label>Cohort B (Empagliflozin + Placebo)</arm_group_label>
    <other_name>JARDIANCE, JARDIANZ, GIBTULIO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic heart failure diagnosed at least 3 months before informed consent

          -  NYHA class II-IV at screening

          -  Body mass index (BMI) &lt;40 kg/m2 at screening

          -  Age ≥ 18 years at screening

          -  Male or female patients. Women of childbearing potential (WOCBP) must be ready and
             able to use highly effective methods of birth control per ICH M3 (R2) that result in a
             low failure rate of less than 1% per year when used consistently and correctly. A list
             of contraception methods meeting these criteria is provided in the patient
             information.

          -  Signed and dated written informed consent in accordance with ICH-GCP and local
             legislation prior to admission to the trial

        Cohort A Heart Failure with Reduced Ejection Fraction (HFrEF)

          -  Left ventricular ejection fraction (LVEF) ≤ 40% as measured by ECHO at screening

          -  The following signs of heart failure;

               -  Elevated NT-proBNP (&gt;125 pg/mL) at screening in patient without atrial
                  fibrillation (AF)

               -  Elevated NT-proBNP (&gt;600 pg/mL) at screening in patient with AF

          -  Appropriate dose of medical therapy for HF (such as ACEi, ARB, β-blocker, oral
             diuretics, MRA, ARNI, ivabradine) consistent with prevailing local and international
             HF guidelines, stable for at least one week prior to Visit 1 and during screening
             period until Visit 2 (Randomisation) with the exception of diuretics which must be
             stable for at least one week prior to Visit 2 to control symptoms. If required, the
             investigator must document in the source documents the reason why the patient is not
             on the target dose per local guidelines.

        Cohort B Heart Failure with Preserved Ejection Fraction (HFpEF)

          -  Left ventricular ejection fraction (LVEF) ≥ 50% as measured by ECHO at screening and
             no previous measurement of LVEF ≤ 40%.

          -  The following combined signs of heart failure;

               -  Structural heart disease (LA enlargement [LAVI &gt;34 mL/m2] and/or LVH [LVMI ≥ 115
                  g/m2 for males and ≥ 95 g/m2 for females]) by ECHO at screening or within 3
                  months prior to informed consent AND

               -  NT-proBNP &gt; 125pg/mL at screening in patient without AF or NT-pro-BNP &gt; 600 pg/mL
                  in patient with AF

          -  Oral diuretics, if prescribed, should be stable for at least one week prior to Visit 1
             and during screening period until Visit 2 (Randomisation).

        Exclusion Criteria:

          -  Stroke or transient ischaemic attack (TIA) within 6 months prior to informed consent.

          -  Any significant coronary artery disease (CAD) with &gt;50% luminal obstruction, unstable
             angina due to significant CAD, percutaneous coronary intervention (PCI), coronary
             artery bypass graft surgery or other major (in the opinion of the investigator)
             cardiovascular surgery.

          -  Any contraindication for MRI, CPET and/or dobutamine stress test in accordance with
             the institution guidance, including implanted left ventricular assist device
             (LVAD),implantable cardioverter defibrillator (ICD), cardiac resynchronisation therapy
             (CRT) or any cardiac device.

          -  Heart transplant recipient or listed for heart transplant

          -  Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation
             diseases (e.g. haemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy
             with reversible causes (e.g. stress cardiomyopathy), hypertrophic obstructive
             cardiomyopathy or known pericardial constriction

          -  Moderate to severe uncorrected valvular heart disease, obstructive or regurgitant, or
             any valvular heart disease expected to lead to surgery in the Investigator's opinion

          -  Acute decompensated HF (exacerbation of chronic HF) requiring intravenous (i.v.)
             diuretics, i.v. inotropes or i.v. vasodilators, or LVAD or hospitalisation within 1
             week prior to Visit 1 (Screening), or during screening period until Visit 2
             (Randomisation)

          -  Systolic blood pressure (SBP) ≥ 180 mmHg at screening. If SBP &gt;150 mmHg and &lt;180mmHg
             at screening, the patient is ineligible if receiving 3 or more antihypertensive drugs

          -  Symptomatic hypotension and/or a SBP &lt; 100 mmHg at Screening

          -  Atrial fibrillation which is uncontrolled in the opinion of the investigator

          -  Untreated ventricular arrhythmia with syncope documented within the 3 months prior to
             informed consent in patients without ICD

          -  Diagnosis of cardiomyopathy induced by chemotherapy or peripartum within the 12 months
             prior to informed consent

          -  Symptomatic bradycardia or second or third degree heart block in need of a pacemaker
             after adjusting beta-blocker therapy or any other negative inotropic agents, if
             appropriate

          -  Chronic pulmonary disease requiring home oxygen, oral steroid therapy or
             hospitalisation for exacerbation within 12 months prior to informed consent, or
             significant chronic pulmonary disease in the Investigator's opinion, or primary
             pulmonary arterial hypertension

          -  Indication of liver disease, defined by serum levels of either ALT (SGPT), AST
             (SGOT),or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at
             screening

          -  Impaired renal function, defined as estimated Creatinine Clearance &lt; 30 mL/min (using
             Cockcroft-Gault formula) or requiring dialysis, as determined at screening

          -  Haemoglobin &lt; 10 g/dL at screening

          -  Type 1 Diabetes Mellitus (T1DM)

          -  History of ketoacidosis

          -  Major surgery (major according to the investigator's assessment) performed within 3
             months prior to informed consent, or scheduled major elective surgery (e.g. hip
             replacement) within 3 months after Visit 1

          -  Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of
             trial medication in the investigator's opinion

          -  Any documented active or suspected malignancy or history of malignancy within 2 years
             prior to informed consent, except appropriately treated basal cell carcinoma of the
             skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with
             pretreatment PSA &lt;10 ng/mL, and biopsy Gleason score of ≤ 6 and clinical stage T1c or
             T2a)

          -  Presence of any other disease than heart failure with a life expectancy of &lt;1 year in
             the investigator's opinion

          -  Patients who must or wish to continue the intake of restricted medications or any drug
             considered likely to interfere with the safe conduct of the trial

          -  Patients with requirement for treatment with empagliflozin according to local standard
             of care

          -  Treatment with any SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor within 1 week
             prior to informed consent or during screening period until Visit 2 (Randomisation)

          -  Currently enrolled in another investigational device or drug study, or less than 30
             days between randomisation and ending another investigational device or drug study, or
             receiving other investigational treatment(s). Patients participating in a purely
             observational trial will not be excluded.

          -  Known allergy or hypersensitivity to empagliflozin or other SGLT-2 inhibitors

          -  Chronic alcohol or drug abuse or any condition that, in the investigator's opinion,
             makes them an unreliable trial subject or unlikely to complete the trial

          -  Women who are pregnant, breastfeeding, or who plan to become pregnant while in the
             trial

          -  Any clinical condition that would jeopardise patients safety while participating in
             this trial, or may prevent the subject from adhering to the trial protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masliza Mahmod</last_name>
      <phone>+44 1865 220245</phone>
      <email>Masliza.mahmod@cardiov.ox.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

